American Society for Microbiology Position on Home Use HIV-1 Testing Patricia Charache, MD Johns Hopkins Medical Institutions Professor of Pathology, Medicine.

Slides:



Advertisements
Similar presentations
HIV Counseling, Testing and Referral (CTR) Services at Boston Medical Center Vanessa J. Sasso, MSW Manager, HIV CTR Program Center for HIV/AIDS Care and.
Advertisements

Point of Care Testing BOPCC May 31, 2011 Beatrice OKeefe, Chief Laboratory Field Services California Department of Public Health.
Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers.
Module 16: Professional Ethics
Principles of FDA Regulation for In Vitro Diagnostic Tests for Home Use Carol C. Benson OIVD/CDRH/FDA March 9, 2011 Molecular and Clinical Genetics Panel.
CLIA Waived Testing for Physician Office Labs Doris Thompson, Ph.D., MT (ASCP) AK State Public Health Laboratories State CLIA Program Francisca Lehr, M.S.,
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
1 Quality System Considerations for Over-The-Counter HIV Testing Devery Howerton, Ph.D. Chief, Laboratory Practice Evaluation and Genomics Branch, Division.
Accessing Valid Health Information, Products, and Services
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download, adapt, and distribute this.
Direct to Consumer Testing Issues. Types of tests being sold Diagnostic tests – identify specific conditions Carrier testing - identify those who carry.
Nurses Registered Nurses - real nurses LPN - licensed practical nurses Nurse Practitioners non-licensed caregivers.
FDA Panel Comments Adele Schneider, MD, FACMG Victor Center for the Prevention of Jewish Genetic Diseases, Director, Clinical Genetics Albert Einstein.
Over The Counter HIV Testing A Technology Whose Time has Come Freya Spielberg, MD MPH
CUMC IRB Investigator Meeting November 9, 2004 Research Use of Stored Data and Tissues.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Quality Control Barbara Weberman MT(ASCP) Oakland County Health Division Laboratory Supervisor.
Introduction to Developing a Vaccination Strategy for Smallpox Preparedness Department of Health and Human Services Centers for Disease Control and Prevention.
HIV Screening, Testing and Treatment in Adolescents January 2012 Meera Beharry, MD Division of Adolescent Medicine University of Rochester Medical Center.
STI Prevention & Control Programs Local and State M. Terry Hogan, MPH STD/HIV Prevention Training Center at JH June 9, 2014 National Center for HIV/AIDS,
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.
CLIA COMPLIANCE. What is CLIA? In 1988 Congress turned its attention to deficiencies in the quality of services provided by the nation’s laboratories.
Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.
Indianapolis Discovery Network for Dementia Forecasting the Future Impact of Early Detection and Management Program for Alzheimer.
An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test 1 An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test OraSure Technologies, Inc.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Essentials Of Business Law Chapter 30 Professionals’ Liability McGraw-Hill/Irwin Copyright © 2007 The McGraw-Hill Companies, Inc. All rights reserved.
Program Collaboration and Service Integration: An NCHHSTP Green paper Kevin Fenton, M.D., Ph.D., F.F.P.H. Director National Center for HIV/AIDS, Viral.
1 Accreditation and Certification: Definition  Certification: Procedures by which a third party gives written assurance that a product, process or service.
Slide #1 What is your clinical/academic training or background? Please select ONE answer that best describes your current primary position 1. Medical doctor.
Unit 8 Presentation Chapter 17
HIPAA UPDATES. HIPAA – KNOWING WHAT IT IS Health Information Portability and Accountability Act “HIPAA” - federal law giving patients certain privacy.
RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.
The policy development for introducing of the oral fluid based rapid HIV test kit in Thailand Writers in the 2009 Write Workshop (WHO Bulletin)
For Pharmacy Tech Training. Goal 1 Assist the pharmacist in collecting, organizing and evaluating information for direct patient care, medication use.
2008© COPYRIGHT Thrombosis and Hemostasis Centers Research and Prevention Network Centers for Disease Control & Prevention Thomas L. Ortel, M.D., Ph.D.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Approaches to Validation of Over-the- Counter (OTC) Home-Use HIV Test Kits Blood Products Advisory Committee November 3, 2005 Elliot P. Cowan, Ph.D. Chief,
Routine Opt-Out HIV Testing Texas STD Clinics James H. Lee, Senior Public Health Advisor HIV/STD Program Texas Department of State Health Services.
1 Findings from Recent Consumer and Health-Care Provider Surveys Adelphi Research by Design supported by sanofi pasteur David R. Johnson, MD, MPHNVAC Meeting.
Public Health Services and Systems Kristine M. Gebbie, DrPH, RN Columbia University School of Nursing Center for Health Policy 630 West 168 th Street,
Introduction to OraQuick Rapid HIV Testing William F. Ryan Community Health Center School Based Health Program.
Using Informatics to Promote Community/Population Health
Legal aspects of Health Data protection Solvita Olsena Medical Law Institute Ltd.
Proposed Studies to Support the Approval of Over-the-Counter (OTC) Home-Use HIV Test Kits Blood Products Advisory Committee March 10, 2006 Elliot P. Cowan,
The Role of LHDs in Improving Population Health LaQuandra S. Nesbitt, MD, MPH Director, LMPHW KHDA Retreat October 9, 2013.
CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.
HIV Testing in Acute Care Settings Rich Rothman, MD, PhD, FACEP CDC, DHHS, OraSure Technologies, Abbott  Historical.
Preparing for the Future of HIV/AIDS Nursing: A Road Map to Success Jason E. Farley, PhD, MPH, CRNP Assistant Professor, Johns Hopkins University School.
PATIENT SAFETY AND QUALITY IMPROVEMENT EDUCATIONAL STRATEGY.
Disclaimer This presentation is intended only for use by Tulane University faculty, staff, and students. No copy or use of this presentation should occur.
ANALYZING THE INTEGRATION OF HIV TESTING INTO THE FLOW OF FAMILY PLANNING CLINICS JANUARY 29, 2009 Rapid Testing & Clinic Flow 1.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
Depart. of Pulmonology 백승숙. More than 80% of cases of tuberculosis in the United States –The result of reactivated latent infection –Nearly all these.
Introduction to Quality Assurance. Quality assurance vs. Quality control.
Kathleen Brady, MD; Coleman Terrell; Marlene Matosky, MPH, RN
Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.
Point of Care Testing California Clinical Laboratory Association
Public Health Interventions
Quality System Considerations for Over-The-Counter HIV Testing
Accountabilities of health and social care practitioners
Quality Control Barbara Weberman MT(ASCP)
AIDS in the United States
Profesionalism and Managerial Skill
Risk and safety management in infertility and assisted reproductive technology (ART): from the doctor's office to the ART procedure  Dominique de Ziegler,
Presentation transcript:

American Society for Microbiology Position on Home Use HIV-1 Testing Patricia Charache, MD Johns Hopkins Medical Institutions Professor of Pathology, Medicine & Oncology

ASM Position Overview Home Use HIV-1 Antibody Testing u Home use HIV-1 antibody testing removes the responsibility for assay performance, result interpretation and counseling from trained professionals. u Erroneous test performance presents a significant risk not only to subjects, but to society as at large. u Such consequences cannot be justified in the name of increased access to testing.

Requirements For Waived Tests Per CLIA law, waived tests must a.Employ methodologies so simple and accurate that erroneous results are negligible, and b. Pose no reasonable risk of harm to the patient if the test is performed incorrectly

Risk of Error with a Home Test Kit u The risk of error in performing the test varies with the nature of the population(s) that purchase and try to use the kit. u With home test kits, the purchasing population cannot be controlled

Risks of Errors of HIV Test Performance u Ability of purchaser to read directions u Ability of purchaser to follow directions u Ability to monitor time and other test requirements u Appropriate conditions at the site of testing u Other

Oraquick Fluid Test: Current Harm Prevention Strategies u The manufacturer will sell the product only to laboratories that have CLIA certification that permits them to do waived tests. u CDC has established requirements that must be followed by all investigators funded by CDC for validation or other studies. These are requirements that are in addition to those that apply for other waived tests. u Some states have also added expanded requirements

Rates of Errors in Waived Testing Studies Rates of Errors in Waived Testing Studies [From the CMS Study of Waived Testing Usage] u [ CMS study in 8 states] corroborated findings of the Colorado/Ohio pilots, OIG, CDC & New York studies u 48% of waived laboratories had quality testing problems u Doctors and nurses were not following the manufacturer’s instructions/CDC QC requirements

Requirements For Waived Tests Per CLIA law, waived tests must a.Employ methodologies so simple and accurate that erroneous results are negligible, and b. Pose no reasonable risk of harm to the patient if the test is performed incorrectly

Risk of Harm u The likelihood of pre-test counseling is low. u The user may not read, understand, and/or follow the directions listed in a subject brochure that describes the test, its interpretations and its follow-up needs. u Risk of failure to obtain confirmatory testing is enhanced in the absence of guidance.

Risk of Harm 2 u The risk of harm will vary with the likelihood that the purchaser is from a high risk population, vs. a member of the worried well, (high vs. low positive predictive value.) u The demographics of the purchaser can never be predicted. u A subject from a low risk population has a high likelihood of a false positive screening test. u False positive screening tests lead to substantial personal harm.

Risk of Harm 3 u Of highest concern to the American Society for Microbiology is the fact that HIV is a contagious disease. u A test error can harm not only the subject, but society as well u HIV is a spreading epidemic. ASM believes that our best current defense is accurate testing performed in association with secure counseling, and opportunity for appropriate post-test guidance and care

Summary u Home use HIV-1 antibody testing removes the responsibility for assay performance, result interpretation and counseling from trained professionals u Erroneous test performance presents a significant risk not only to subjects, but to society as at large. u Such consequences cannot be justified in the name of increased access to testing.